PHARMACO-ECONOMIC STUDY OF INTRA-ARTCULAR HYALORONIC ACID VS INTRA- ARTICULAR CORTICOSTEROID IN EGYPTIAN PATIENTS RECEIVING STANDARD CARE THERAPY

Asmaa Ahmed M. Badawy a , **Hanan Saady Zaki** b , **Mohamed El Taher M. Wasfy** c , **Nourhan Tarek** d , **Noura Ahmed Shawky** e

a **BCCCP , PD OF PHARMACOTHERAPY , FHTA , CLINICAL PHARMACIST MISR UNIVERSITY FOR SCIENCE AND TECHNOLOGY HOSPITAL .**

b **EGYPTIAN drug AUTHORITY ,** c **MEDICAL MANAGER AT IPS GENOMIX ,**

d **HEALTH ECONOMICS&VALUE UNIT 57357 HOSPITAL ,** e **HTA FELLOW .**

• Abstract



https://www.healthline.com/health/osteoarthritis

• Objective

- evaluate the cost-effectiveness of intra-articular hyaluronic acid vs intra-articular corticosteroids vs the standard Egyptian regimen with mild to moderate osteoarthritis.

• Methods

- A decision tree model was developed based on the Egyptian clinical practice for 6 months , analysis was derived from FLEXX trials double blind randomized and cost effectiveness of bioengineered HA from published sources .
- This decision analytical model was constructed to assess the costs and consequences associated with intra- articular hyaluronic acid containing regimen compared with intra -articular corticosteroids or receiving standard therapy (NSAIDS) from patient persepective .
- Sensitivity analyses were conducted +20% &-20%





- The utility of the health states was derived using the available published data. In our calculation , Direct medical costs were obtained from the local market prices in 2019 and from the expert orthopedic doctors about the average produre cost .

Results

- for IA CCS total cost of 1ry responsder 2265.1, total cost of 2nd responder 2786.9 and total cost of 2nd non-responder 5619.40 for IA HA the total cost of 1ry responder 4680.5 , total cost of 2nd responder7216.16 and the total cost of 2nd non responder was 8762.63 : IA HA is a cost effective option either vs NSAIDs or vs IA-CCs (ICER are 32081.17113 and 19617.53) respectively

• CONCLUSION

- IA-HA in treatment of mild to moderate OA patients is cost –effective option based on who (3GDP/ Capita) .

• References

- Hatoum, H. T., Fierlinger, A. L., Lin, S. J., & Altman, R. D. (2014). Journal of medical economics, 17(5), 326-337.
- Maricar, N., Parkes, M. J., Callaghan, M. J., Hutchinson, C. E., Gait, A. D., Hodgson, R., ... & O'Neill, T. W. (2017. Arthritis research & therapy, 19(1), 88.
- Altman, R. D., Rosen, J. E., Bloch, D. A., Hatoum, H. T., & Korner, P. (2009, August). (The FLEXX Trial). In Seminars in arthritis and rheumatism (Vol. 39, No. 1, pp. 1-9). WB Saunders.
- Raynauld, J. P., Torrance, G. W., Band, P. A., Goldsmith, C. H., Tugwell, P., Walker, V., ... & Bellamy, N. (2002 (Part 1 of 2): clinical results. Osteoarthritis and Cartilage, 10(7), 506-517.

ISPOR
Improving healthcare decisions

Asmaa Ahmed Mohamed
dr_asmaa2005@yahoo.com
Asmaa.ahmed@skuh.org